Diabetes medications with cardiovascular protection - What now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?

Robert Ej Ryder; Ralph A. DeFronzo

doi:10.15277/bjd.2016.096

Diabetes medications with cardiovascular protection - What now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?

Robert Ej Ryder, Ralph A. DeFronzo

Division of Diabetes

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	103-106
Number of pages	4
Journal	British Journal of Diabetes and Vascular Disease
Volume	16
Issue number	3
DOIs	https://doi.org/10.15277/bjd.2016.096
State	Published - Jul 1 2016

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.15277/bjd.2016.096

Cite this

Diabetes medications with cardiovascular protection - What now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? / Ryder, Robert Ej; DeFronzo, Ralph A.
In: British Journal of Diabetes and Vascular Disease, Vol. 16, No. 3, 01.07.2016, p. 103-106.

Research output: Contribution to journal › Review article › peer-review

@article{5929b2f676a04997a6c26005d8874cc1,

title = "Diabetes medications with cardiovascular protection - What now after LEADER{\textregistered}? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?",

author = "Ryder, {Robert Ej} and DeFronzo, {Ralph A.}",

year = "2016",

month = jul,

day = "1",

doi = "10.15277/bjd.2016.096",

language = "English (US)",

volume = "16",

pages = "103--106",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",